Outcome of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology

Abstract

Introduction: Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a significant therapeutic agent in the management of type 2 diabetes mellitus (T2DM). Objectives: This study aims to explore the outcomes of dapagliflozin use in real-life clinical settings, focusing on its impact on glycemic control, cardiovascular health, renal function, and overall patient quality of life. Methodology of the study: This observational study was conducted at Faisalabad Medical university from June 2023 to March 2024. Data were collected from 240 patients who visited the OPD of the hospital. Data were collected from electronic medical records (EMRs). Demographic information, age, gender, body mass index (BMI), duration of diabetes was noted in a systematically designed performa. Clinical parameters, HbA1c, fasting blood glucose (FBG), systolic and diastolic blood pressure (SBP, DBP) were measured. Results: The study included 240 patients with T2DM who were prescribed dapagliflozin. The cohort comprised 130 males (54.2%) and 110 females (45.8%), with a mean age of 58.3 ± 10.2 years. The average body mass index (BMI) was 31.5 ± 4.8 kg/m², and the mean duration of diabetes was 8.6 ± 5.1 years. At the 6-month follow-up, patients demonstrated a significant reduction in HbA1c, with a mean decrease of 1.2% ± 0.8% (p < 0.001). FBG levels also showed a notable decline, with a mean reduction of 35 ± 30 mg/dL (p < 0.001). Conclusion: This study reinforces the effectiveness and safety of dapagliflozin in managing T2DM. The significant improvements in glycemic control, blood pressure, and weight, along with a favorable safety profile, highlight dapagliflozin’s utility in routine clinical practice.